883 related articles for article (PubMed ID: 28121498)
21. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.
Zeng Z; Zhao H; Dorr MB; Shen J; Wilcox MH; Poxton IR; Guris D; Li J; Shaw PM
Anaerobe; 2020 Feb; 61():102137. PubMed ID: 31846705
[TBL] [Abstract][Full Text] [Related]
22. Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.
Kelly CP; Poxton IR; Shen J; Wilcox MH; Gerding DN; Zhao X; Laterza OF; Railkar R; Guris D; Dorr MB
Clin Infect Dis; 2020 Jun; 71(1):81-86. PubMed ID: 31628838
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
[TBL] [Abstract][Full Text] [Related]
24. Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).
Sferra TJ; Merta T; Neely M; Murta de Oliveira C; Lassaletta A; Fortuny Guasch C; Dorr MB; Winchell G; Su FH; Perko S; Fernsler D; Waskin H; Holden SR
J Pediatric Infect Dis Soc; 2023 Jun; 12(6):334-341. PubMed ID: 37389891
[TBL] [Abstract][Full Text] [Related]
25. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
Villafuerte Gálvez JA; Kelly CP
Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
[TBL] [Abstract][Full Text] [Related]
26. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.
Prabhu VS; Cornely OA; Golan Y; Dubberke ER; Heimann SM; Hanson ME; Liao J; Pedley A; Dorr MB; Marcella S
Clin Infect Dis; 2017 Oct; 65(7):1218-1221. PubMed ID: 30060024
[TBL] [Abstract][Full Text] [Related]
27. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
29. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
30. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent
Alhifany AA; Almutairi AR; Almangour TA; Shahbar AN; Abraham I; Alessa M; Alnezary FS; Cheema E
BMJ Open; 2019 Nov; 9(11):e031145. PubMed ID: 31699731
[TBL] [Abstract][Full Text] [Related]
31. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
[TBL] [Abstract][Full Text] [Related]
32. Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis.
Paschos P; Ioakim K; Malandris K; Koukoufiki A; Nayfeh T; Akriviadis E; Tsapas A; Bekiari E
Anaerobe; 2021 Oct; 71():102441. PubMed ID: 34454094
[TBL] [Abstract][Full Text] [Related]
33. ▼ Bezlotoxumab for prevention of recurrence of Clostridium difficile infection.
Drug Ther Bull; 2018 May; 56(5):57-60. PubMed ID: 29760164
[No Abstract] [Full Text] [Related]
34. AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.
Guilleman MM; Stevens BAY; Van Lieshout LP; Rghei AD; Pei Y; Santry LA; Thompson B; Wootton SK
Gene Ther; 2023 May; 30(5):455-462. PubMed ID: 33608675
[TBL] [Abstract][Full Text] [Related]
35. Bezlotoxumab for the prevention of Clostridium difficile recurrence.
Couture-Cossette A; Carignan A; Ilangumaran S; Valiquette L
Expert Opin Biol Ther; 2017 Nov; 17(11):1439-1445. PubMed ID: 28805081
[TBL] [Abstract][Full Text] [Related]
36. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
37. Bezlotoxumab for Preventing Recurrent Clostridium difficile Infections.
Rounds J; Strain J
S D Med; 2017 Sep; 70(9):422-423. PubMed ID: 28863256
[No Abstract] [Full Text] [Related]
38. Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.
Wilcox MH; Rahav G; Dubberke ER; Gabryelski L; Davies K; Berry C; Eves K; Ellison MC; Guris D; Dorr MB
Open Forum Infect Dis; 2019 Aug; 6(8):. PubMed ID: 31375837
[TBL] [Abstract][Full Text] [Related]
39. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
